Kleczko, Emily K. http://orcid.org/0000-0003-4254-5415
Hinz, Trista K.
Nguyen, Teresa T.
Gurule, Natalia J.
Navarro, Andre
Le, Anh T.
Johnson, Amber M.
Kwak, Jeff
Polhac, Diana I.
Clambey, Eric T.
Weiser-Evans, Mary
Merrick, Daniel T.
Yang, Michael C.
Patil, Tejas http://orcid.org/0000-0003-4389-1010
Schenk, Erin L. http://orcid.org/0000-0001-9418-9948
Heasley, Lynn E. http://orcid.org/0000-0001-8056-0208
Nemenoff, Raphael A. http://orcid.org/0000-0002-2369-2535
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA236222)
U.S. Department of Defense (W81XWH1910220, W81XWH1910220)
Article History
Received: 5 October 2022
Accepted: 18 January 2023
First Online: 4 February 2023
Competing interests
: E.L.S. reports speaker fees from the American Lung Association, American Society of Clinical Oncology, OncLive, Physicians Education Resource, Takeda, and Roche/Genentech. E.L.S. reports consultant fees from Actinium, Bionest Partners, ExpertConnect, FCB Health, Guidepoint Network, the KOL Connection Ltd, and the ROS1ders. E.L.S. is on the Scientific Advisory Board for Regeneron and Janssen. E.L.S. reports research funding from Takeda. T.P. is on the advisory boards for AstraZeneca, Pfizer, EMD Soreno, Janssen, Mirati Therapeutics, Sanofi, and Takeda. T.P. has studies that are sponsored by EMD Soreno and Janssen. T.P. has no research funding to disclose. No disclosures were reported by the other authors.